Eye movement abnormalities in AQP4-IgG positive neuromyelitis optica spectrum disorder

被引:4
|
作者
Sun, Houliang [1 ]
Cui, Shilei [1 ]
Gao, Fei [1 ]
You, Qisheng [2 ]
Li, Yong [3 ]
Wang, Jiawei [1 ]
Zhang, Xiaojun [1 ]
机构
[1] Capital Med Univ, Beijing Tongren Hosp, Dept Neurol, 1 Dong Jiao Min Xiang, Beijing 100730, Peoples R China
[2] Capital Med Univ, Beijing Tongren Hosp, Ophthalmol Ctr, Beijing, Peoples R China
[3] Capital Med Univ, Beijing Tongren Hosp, Dept Radiol, Beijing, Peoples R China
关键词
Neuromyelitis optica spectrum disorder; Eye movement; Saccade; Visual handicap; MULTIPLE-SCLEROSIS; DIAGNOSTIC-CRITERIA; BRAIN-STEM; MANIFESTATIONS; DISTINCTION; ANTIBODY; MS;
D O I
10.1016/j.jns.2017.11.033
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and purpose: Neuromyelitis optica spectrum disorder (NMOSD) has been recognized as a disease characterized by severe visual afferent impairment. Abnormal eye movements, as the other important neuroophthalmic manifestation of NMOSD, were commonly overlooked. The aim of our study was to describe the ocular motor manifestations of AQP4-IgG positive NMOSD patients, and explore the value of eye movement abnormalities in the evaluation of the disabled disease. Methods: Systemic clinical bedside ocular motor examinations and quantitative horizontal saccadic eye movement assessments were performed in 90 patients with AQP4-IgG positive NMOSD. General disability was evaluated by expanded disability status scale (EDSS). Vision-specific functional status was evaluated by the National Eye Institute-Visual Function Questionnaire (NEI-VFQ 25) and the 10-item neuro-ophthalmic supplement. Brain magnetic resonance imaging (MRI) was acquired in all patients. Results: In clinical examination, eye movement abnormalities were found in 38% of NMOSD patients. Abnormalities in the quantitative saccadic test were found in 67% of NMOSD patients, including 48% of patients with clinically normal eye movements. EDSS scores in patients with clinical eye movement abnormality were significantly higher (P < 0.001) than those with a normal examination. The 10-item neuro-ophthalmic supplement score was significantly associated with quantitative saccadic eye movement abnormalities (P = 0.031). Conclusions: Eye movement abnormalities were common in AQP4-IgG positive NMOSD patients, and were associated with general disability and specific visual handicap. The systemic clinical eye movement examination combined with the quantitative saccade test was easy to perform, and could provide additional useful information in evaluating NMOSD.
引用
收藏
页码:91 / 95
页数:5
相关论文
共 50 条
  • [31] Early predictors of disability of paediatric-onset AQP4-IgG seropositive neuromyelitis optica spectrum disorders
    Camera, V.
    Messina, S.
    Elhadd, K. T.
    Sanpera-Iglesias, J.
    Mariano, R.
    Hacohen, Y.
    Dobson, R.
    Meletti, S.
    Wassmer, E.
    Lim, M.
    Huda, S.
    Hemingway, C.
    Leite, M. I.
    Ramdas, S.
    Palace, J.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 149 - 150
  • [32] EBI2-expressing B cells in neuromyelitis optica spectrum disorder with AQP4-IgG: Association with acute attacks and serum cytokines
    Baek, Seol-Hee
    Kim, Boram
    Shin, Je-Young
    Choi, Seok-Jin
    Ahn, So Hyun
    Choi, Youn Soo
    Kim, Sung-Min
    Sung, Jung-Joon
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 2021, 358
  • [33] A multi-facet comparative analysis of neuromyelitis optica spectrum disorders in patients with seropositive and seronegative AQP4-IgG
    Wang, Xiaojuan
    Chen, Xiaoyang
    Zhu, Chaoxia
    Ma, Haichang
    Wang, Fang
    Qin, Lingzhi
    Li, Wei
    [J]. MEDICINE, 2018, 97 (48)
  • [34] Pregnancy-Related Attack in Neuromyelitis Optica Spectrum Disorder With AQP4-IgG: A Single-Center Study and Meta-Analysis
    Deng, Shuwen
    Lei, Qiang
    Lu, Wei
    [J]. FRONTIERS IN IMMUNOLOGY, 2022, 12
  • [35] Effectiveness of mycophenolate mofetil as first line therapy in AQP4-IgG, MOG-IgG and seronegative neuromyelitis optica spectrum disorders
    Montcuquet, A.
    Collongues, N.
    Papeix, C.
    Zephir, H.
    Audoin, B.
    Laplaud, D.
    Bourre, B.
    Brochet, B.
    Camdessanche, J-P
    Labauge, P.
    Moreau, T.
    Stankoff, B.
    De Seze, J.
    Vukusic, S.
    Marignier, R.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 282 - 283
  • [36] Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica
    Duan, Tianjiao
    Smith, Alex J.
    Verkman, Alan S.
    [J]. JOURNAL OF NEUROINFLAMMATION, 2018, 15
  • [37] Prolonged B-cell depletion after rituximab in AQP4-IgG-positive neuromyelitis optica spectrum disorder
    Sechi, Elia
    Zarbo, Roberto
    Biancu, Maria Angela
    Chessa, Paola
    Idda, Maria Laura
    Orru, Valeria
    Lai, Sandra
    Leoni, Stefania
    Solla, Paolo
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 2021, 358
  • [38] Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica
    Tianjiao Duan
    Alex J. Smith
    Alan S. Verkman
    [J]. Journal of Neuroinflammation, 15
  • [39] AQP4-IgG-positive neuromyelitis optica spectrum disorder and temporally detected neoplasms: case report and systematic review
    Apiraksattayakul, Natnasak
    Songwisit, Sakdipat
    Owattanapanich, Weeraphat
    Tisavipat, Nanthaya
    Siritho, Sasitorn
    Prayoonwiwat, Naraporn
    Rattanathamsakul, Natthapon
    Jitprapaikulsan, Jiraporn
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 68
  • [40] Efficacy and Safety of Satralizumab in Adults with AQP4-IgG Seropositive Neuromyelitis Optica Spectrum Disorder (NMOSD): Results from the Phase 3 SAkura Studies
    Bennet, J. L.
    Fox, E.
    Greenberg, B. M.
    Weinshenker, B. G.
    Blondeau, K.
    Weber, K.
    Gholizadeh, S.
    Stokmaier, D.
    von Budingen, H.
    Traboulsee, A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (1_SUPPL) : 80 - 80